Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants
Paul M. Steed(Serdang Hospital), Bassil I. Dahiyat(University of California San Diego), Jonathan Zalevsky(Nektar Therapeutics (United States)), David F. Carmichael(Xencor (United States)), Alice Kim(York University), Sandhya Kashi(Xencor (United States)), Lisa Cherry(Xencor (United States)), Omid Vafa(Xencor (United States)), John R. Desjarlais(Xencor (United States)), Donald O. O'Keefe(Xencor (United States)), Linus Hyun(Xencor (United States)), Sarah X. Gao(Xencor (United States)), Christina M. Abbott(Amgen (United States)), Sean C. Yoder(Xencor (United States)), David E. Szymkowski(Xencor (United States)), Peter Cheung(Délégation Paris 5), René Hubert(Xencor (United States)), Karen L. Singer(Xencor (United States)), Umesh S. Muchhal(IGM Biosciences (United States)), Araz Eivazi(Xencor (United States)), Cheryl Chan(Xencor (United States)), Eugene A. Zhukovsky(Xencor (United States)), Jost Vielmetter(Xencor (United States)), James Kung(Xencor (United States)), Marian Y. Hwang(Xencor (United States)), Duc-Hanh T. Nguyen(Xencor (United States)), Stephen K. Doberstein(Xencor (United States)), Sabrina P. Martinez(Xencor (United States)), Christopher J. O’Brien(Children’s Health Queensland Hospital and Health Service), Arthur J. Chirino(Amgen (United States)), Anton V. Filikov(Xencor (United States)), Esther Kim(Springer Nature (New Zealand)), Malú G. Tansey(University of Florida)
Cited by 259
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Efficiency of signalling through cytokine receptors depends critically on receptor orientation
|Nature|1998|555
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403